hero section gradient
18 handpicked stocks

Once-In-A-Decade

This collection features companies that profit from life's biggest purchases - the ones you make only a few times. Carefully selected by our analysts, these businesses excel at maximizing value from milestone transactions like homes, vehicles, and luxury goods.

Author avatar

Han Tan | Market Analyst

Published on June 17

Your Basket's Financial Footprint

Interpretation of the 'Once-In-A-Decade' basket market capitalisation and investor takeaways based on the provided breakdown.

Key Takeaways for Investors:
  • Large-cap dominance tends to provide stability, lower volatility, and closer tracking of broad market movements.
  • Treat as a core holding within a diversified portfolio rather than a speculative, high-growth allocation.
  • Expect steady, long-term appreciation rather than explosive short-term gains; growth tends to be gradual.
Total Market Cap
  • DHI: $47.29B

  • LEN: $32.45B

  • PHM: $24.03B

  • Other

About This Group of Stocks

1

Our Expert Thinking

These companies focus on high-value, infrequent consumer spending - the major purchases that mark life milestones. We've identified businesses whose profits come from transactions consumers might make just a handful of times, creating stable revenue even with less frequent sales.

2

What You Need to Know

These stocks tend to be sensitive to consumer confidence, disposable income, and interest rates. When financing is affordable and economic optimism is high, these companies often flourish. They're cyclical by nature but driven by essential purchases that consumers will eventually make.

3

Why These Stocks

We've selected industry leaders with strong brand recognition and impressive revenue-per-transaction metrics. These companies have demonstrated staying power in markets defined by infrequent but significant consumer spending, with business models built to capture maximum value from each sale.

Why You'll Want to Watch These Stocks

🏠

The Big-Ticket Advantage

These companies capture substantial profits from each transaction, often with higher margins than everyday purchase businesses. A single sale can significantly impact quarterly results.

📉

Rate-Cut Opportunity

As interest rates potentially decline, financing for big purchases becomes more affordable. This could trigger pent-up demand for homes, vehicles, and other major investments.

💎

Life's Milestone Moments

These companies provide products for life's most significant moments - from first homes to engagement rings. Even in challenging economies, these purchases may be delayed but rarely abandoned.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions